![](https://investorshub.advfn.com/uicon/108458.png?cb=1482855649)
Sunday, July 16, 2023 1:06:13 PM
GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform
![](http://investorshub.advfn.com/uimage/uploads/2023/7/16/ybjdtIMG_0495.gif)
and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent ARCT News
- Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 • Business Wire • 07/18/2024 11:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/17/2024 09:27:11 PM
- Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs • Business Wire • 07/01/2024 08:01:00 PM
- Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors • Business Wire • 06/20/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:01:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:00:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:36 PM
- Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference • Business Wire • 06/07/2024 02:30:00 PM
- Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program • Business Wire • 05/28/2024 10:30:00 AM
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine • Business Wire • 05/20/2024 12:30:00 PM
- Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine • PR Newswire (US) • 05/20/2024 12:30:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 05/15/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:17:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:04 PM
- Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress • Business Wire • 05/08/2024 08:01:00 PM
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 • Business Wire • 04/25/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:05:52 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress • Business Wire • 03/07/2024 09:01:00 PM
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 02/26/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:35 PM
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 02/22/2024 01:30:00 PM
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 • Business Wire • 02/20/2024 02:00:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • PR Newswire (US) • 02/05/2024 01:30:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • Business Wire • 02/05/2024 01:30:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM